Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials
Journal of the European Academy of Dermatology and Venereology Mar 12, 2018
Gottlieb AB, et al. - Authors evaluated the effect of brodalumab (an interleukin-17 receptor A antagonist) on lesional symptoms in psoriasis patients using the psoriasis symptom inventory (PSI), a validated patient-reported instrument. Compared to placebo and ustekinumab, brodalumab demonstrated rapid, robust improvements in symptoms assessed by the PSI, including itch.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
